T cells are crucial for immune functions to maintain health and prevent disease. T cell
development occurs in a stepwise process in the thymus and mainly generates CD4+ and …

CD8+ T cells are end effectors of cancer immunity. Most forms of effective cancer
immunotherapy involve CD8+ T cell effector function. Here, we review the current …

INTRODUCTION Cancer immunotherapies that target tumor-specific T cells have benefited
many cancer patients, but the clinical efficacy varies greatly among different cancer types …

Immune checkpoint therapy (ICT) can provide durable clinical responses and improve
overall survival. However, only subsets of patients with specific tumor types respond to ICT …

INTRODUCTION More than 50% of patients treated with chimeric antigen receptor (CAR)–T
cells for B cell malignancies develop progressive disease after CAR therapy, and these …

The adoptive transfer of T cells that are engineered to express chimeric antigen receptors
(CARs) has shown remarkable success in treating B cell malignancies but only limited …

CD8+ T cell exhaustion is a major barrier to current anti-cancer immunotherapies. Despite
this, the developmental biology of exhausted CD8+ T cells (Tex) remains poorly defined …

Several non-redundant features of the tumour microenvironment facilitate
immunosuppression and limit anticancer immune responses. These include physical …

Anti-PD-1 treatment has shown unprecedented clinical success in the treatment of non-small-
cell lung cancer (NSCLC), but the underlying mechanisms remain incompletely understood …

Expansion and differentiation of antigen-experienced PD-1+ TCF-1+ stem-like CD8+ T cells
into effector cells is critical for the success of immunotherapies based on PD-1 blockade …